T. Rowe Price Associates
SLN

T. Rowe Price Associates’s Silence Therapeutics SLN Stock Holding History

T. Rowe Price Associates’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-228,644
Closed -$4.16M – 3054
2024
Q3 		$4.16M Buy
+228,644
New +$4.25M ﹤0.01% 1353

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

T. Rowe Price Associates's SLN Position: Q4 2024 in Review

T. Rowe Price Associates sold out of Silence Therapeutics (SLN) in Q4 2024, closing a stake of 228,644 shares — an estimated $4.16M sold.

T. Rowe Price Associates first reported a position in SLN in Q3 2024 and held it in 1 quarter. The position peaked at $4.16M in Q3 2024. 65 funds tracked by Wall St. Rank hold SLN as of Q4 2024.

  • T. Rowe Price Associates reported no remaining Silence Therapeutics position as of Q4 2024 after selling out during the quarter.
  • T. Rowe Price Associates sold 228,644 Silence Therapeutics shares in Q4 2024, an estimated $4.16M.
  • T. Rowe Price Associates first reported a position in Silence Therapeutics in Q3 2024 and held it in 1 quarter.
  • T. Rowe Price Associates's Silence Therapeutics position peaked at $4.16M in Q3 2024.
  • 65 funds tracked by Wall St. Rank held Silence Therapeutics as of Q4 2024.

Based on T. Rowe Price Associates's 13F filing for Q4 2024, filed 14 Feb 2025.